Abstract
In this issue, Lee et al. describe their centres’ experience with drug eluting technologies in the treatment of native femoropopliteal disease in patients with intermittent claudication and chronic limb threatening ischaemia (CLTI).1 Although not a randomised trial, the results probably provide a good comparison of drug coated balloon (DCB) and drug eluting stent (DES) treatment because of the propensity score matching that was performed, and because “real world” pathology was treated with mean lesion lengths of 164.2 mm and 194.8 mm in the DCB and DES groups, respectively.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Paper Title
Journal
Date
